TipRanks on MSN
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
The large-mass animal crossover bioequivalence study will commence in the next two to three weeks and will be carried out ...
New York, USA, October 22nd, 2025, FinanceWire BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company ...
In recent days, Charles River Laboratories International announced several new collaborations, including with The Francis Crick Institute to accelerate Antibody-Drug Conjugate development and with ...
A drug for pulmonary fibrosis created using artificial intelligence (AI) is showing early promise in patients.
The current pharmaceutical landscape demands a change in mindset. Success requires balancing speed, cost and quality while ...
ChemDiv today announced the extension of its discovery and early development partnership with Mondego Bio to advance the company's best-in-class immuno-oncology program targeting PTPN2. The ...
Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...
In the rapidly evolving pharmaceutical landscape, drug discovery services have become a pivotal axis around which innovation, efficiency and competitiveness rotate. According to a recent market report ...
Responses observed at all doses evaluated at 3.2mg/kg and above demonstrating wide therapeutic index of Zymeworks’ novel antibody-drug conjugate platform VANCOUVER, British Columbia, Oct. 23, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback